Kamada Ltd..
KMDA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Kamada Ltd. is a biopharmaceutical company specializing in the development, manufacturing, and marketing of plasma-derived protein therapeutics. The company's product portfolio includes intravenous and inhaled Alpha-1 Antitrypsin (AAT) products for the treatment of Alpha-1 Antitrypsin Deficiency (AA...Show More
Better Health for All
-20
Kamada's core business involves developing, producing, and marketing life-saving plasma-derived protein therapeutics for various diseases and conditions, including rabies, CMV, AATD, hepatitis B, varicella, hemolytic disease of newborns, and snake bites.
1
All listed products are health-positive, resulting in no revenue from products with negative health impacts. The company focuses on orphan indications and high-risk patient groups, such as immunocompromised children, newborns, pregnant women, and solid organ transplant recipients, with AATD affecting 1 in 1,600 to 1 in 5,000 people.
2
Kamada invested in R&D for several pharmaceutical product candidates, including an inhaled AAT for AATD, and has five late-stage plasma-derived protein products in development.
3
The company initiated development of an Anti-SARS-CoV-2 polyclonal immunoglobulin product in early 2020 as a potential COVID-19 treatment.
4
However, the company discontinued its Phase 3 Inhaled AAT Clinical Trial in December 2025.
5
Kamada's policy is to avoid direct commercial involvement with patients, referring them to treating physicians.
6
The company discloses that plasma-derived products are susceptible to contamination and may contain human pathogens, and that their use may produce undesirable side effects or adverse reactions.
7
CYTOGAM, for example, has contraindications and is associated with risks including renal dysfunction, acute renal failure, and death, particularly at doses of 350 mg/kg or greater.
8
The company has a whistleblower policy for reporting accounting, internal accounting controls, or auditing matters, but no specific evidence of transparency regarding health risks and benefits beyond product disclosures.
9
Kamada states it abides by all relevant laws concerning information about employees and confidential business information, but there is no evidence of specific privacy safeguards for patient health data.
10
The company provides training for employee growth and development and has clear promotion processes and fair salary differentials.
11
Kamada conducts human clinical trials and abides by all required laws and guidelines of ethics committees, including ICH-GCP laws, but there is no evidence of specific ethical frameworks beyond compliance.
12
Fair Money & Economic Opportunity
0
Kamada Ltd. is a biopharmaceutical company specializing in plasma-derived protein therapeutics. The provided articles detail its financial performance, regulatory agreements related to clinical trials, and general ESG risk profile within the pharmaceutical industry. There is no evidence in the articles to suggest that Kamada Ltd. offers lending, insurance, or other financial services to consumers.
1
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to the company's core business activities, aligning with the '0' tier definitions for each KPI.
Fair Pay & Worker Respect
20
Kamada Ltd. reports a CEO total compensation of US$795,000.
1
The median employee salary is $120,126, resulting in a CEO to median employee pay ratio of approximately 6.62:1.
2
Employee satisfaction is rated at 3.8 out of 5 stars.
3
,
4
85% of employees recommending working at Kamada.
5
,
6
The company has no reported regulatory actions, violations, fines, or compliance issues in the provided articles.
7
,
8
,
9
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles for Kamada Ltd. (KMDA.US) regarding fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical sourcing clauses in contracts, spend on high-risk materials, or supplier diversity.
1
The articles explicitly state 'Limited information' or 'No data' for these metrics concerning Kamada Ltd.
2
Information related to supplier codes of conduct or conflict minerals in the provided articles pertains to other companies, not KMDA.US.
3
Honest & Fair Business
-40
Kamada Ltd. has a whistleblower policy that outlines detailed procedures for reporting accounting matters and explicitly prohibits retaliation.
1
A whistleblower form is available on the company's website.
2
However, there is no evidence provided regarding independent investigation processes, training, uptake rates, or resolution times for reported cases.
Kind to Animals
0
No specific, concrete evidence was found in the provided articles to assess Kamada Ltd. against the 'Kind to Animals' ethical value across any of the defined Key Performance Indicators. The articles primarily focus on product information, financial performance, and regulatory approvals, without detailing practices related to cruelty-free certifications, alternative testing methods, humane certifications for animal operations, wildlife conservation impact, ethical input substitution, supplier welfare audits, cage-free sourcing, animal testing policy or volume, innovation investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement on animal welfare.
No War, No Weapons
0
No evidence was found in the provided articles to assess Kamada Ltd. against any of the KPIs for the 'No War, No Weapons' ethical value. The articles explicitly state that no data is provided or applicable for metrics such as revenue from arms contracts, R&D investment in dual-use technologies, sales to embargoed regimes, peacebuilding investment, or any other conflict-related activities.
1
Kamada Ltd. is described as a biopharmaceutical company, and the available information focuses on its medical products and general ESG profile, without mention of any defense or arms-related business.
2
Therefore, all KPIs are omitted due to a complete lack of specific, concrete data points.
Planet-Friendly Business
0
No evidence available to assess Kamada Ltd. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific, concrete evidence was found in the provided articles to score any of the KPIs related to 'Respect for Cultures & Communities'. The articles contain general statements about supporting communities and promoting well-being, but lack quantitative data or specific details on formal partnerships with community groups, reinvestment in local development, cultural impact assessments, local employment ratios, community-specific grievance mechanisms, or cultural preservation efforts.
1
The whistleblower and grievance mechanisms mentioned are primarily for internal employees regarding company misconduct, not explicitly for external community concerns.
2
Safe & Smart Tech
0
No evidence was found in the provided articles that is relevant to Kamada Ltd. (KMDA.US) regarding Safe & Smart Tech. The article discusses a settlement related to a class action lawsuit against East Carolina Health (EC Health).
1
Zero Waste & Sustainable Products
0
No information regarding Kamada Ltd.'s waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education was found in the provided articles.
1
The articles focus on financial performance, regulatory actions, and manufacturing capabilities.
2